CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.
CCHIO 2024 | Dr. Xiuyi Zhi: Systematizing Popular Science Efforts to Enhance Public Knowledge, Trust, and Action in Cancer Prevention and Control

CCHIO 2024 | Dr. Xiuyi Zhi: Systematizing Popular Science Efforts to Enhance Public Knowledge, Trust, and Action in Cancer Prevention and Control

The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded on November 17, emphasizing a multidisciplinary approach to oncology. The event featured specialized sessions on integrated rehabilitation, public education, and cancer prevention, showcasing novel perspectives and techniques for comprehensive cancer care. During the conference, Oncology Frontier had the honor of interviewing Dr. Xiuyi Zhi, Chief Expert of Thoracic Surgery at Xuanwu Hospital, Capital Medical University, and Director of the Public Education Department of the Chinese Anti-Cancer Association (CACA). Professor Zhi shared the progress in cancer education initiatives and the development of cancer prevention awareness in China.

CCHIO 2024丨Dr. Xiufeng Liu: Exploring the Clinical Potential of the “Cola Combination” from LEAP-002 to LEAP-012

The era of immunotherapy has brought new hope to advanced hepatocellular carcinoma (HCC), with various targeted-immune combination therapies emerging as potential breakthroughs. However, the journey of the "Cola Combination"—pembrolizumab combined with lenvatinib—has been marked by mixed results. In the LEAP-002 trial, the combination showed negative results in the general population but positive outcomes in the Asian subgroup. The LEAP-012 trial further demonstrated the combination's efficacy when paired with transarterial chemoembolization (TACE) in intermediate-stage HCC. Yet, its precise role in clinical practice remains under discussion.
CTI 2024 | Dr. Ibrahim Yakoub-Agha Discusses the Application of Cellular Immunotherapy in Myelofibrosis

CTI 2024 | Dr. Ibrahim Yakoub-Agha Discusses the Application of Cellular Immunotherapy in Myelofibrosis

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the fields of cell therapy and immune therapy from around the world. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Ibrahim Yakoub-Agha from the Lille University , France, to reveal the unlimited potential and broad prospects of cellular immunotherapy in myelofibrosis.
Saluting Tradition, Building the Future: Prof. Han Kwang Yang Discusses the Mission and Vision of the Asian Oncology Society

Saluting Tradition, Building the Future: Prof. Han Kwang Yang Discusses the Mission and Vision of the Asian Oncology Society

On November 15, 2024, the 4th Asian Oncology Society opened grandly in Xi'an, China. Held alongside the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), this event, co-hosted by the Chinese Anti-Cancer Association and the Asian Oncology Society (AOS), was themed "Integration and Modernity." It brought together oncology experts from across Asia to explore new cancer control strategies and clinical practice advancements. During the conference, Oncology Frontier had the privilege of interviewing Prof. Han Kwang Yang, Secretary-General of AOS and a renowned expert from Seoul National University Hospital, to discuss AOS’s mission and vision for the future.
CCHIO 2024 | Prof. Winckworth-Prejsnar: Advancing Evidence-Based Cancer Treatment through Global Collaboration

CCHIO 2024 | Prof. Winckworth-Prejsnar: Advancing Evidence-Based Cancer Treatment through Global Collaboration

From November 14–17, the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the Asian Oncology Society (AOS 2024) convened in Xi'an. Jointly organized by the Chinese Anti-Cancer Association (CACA), the Union for International Cancer Control (UICC), and the National Comprehensive Cancer Network (NCCN®), the event featured a specialized session on "International Collaboration: CACA-UICC & CACA-NCCN."
The academic grand event on urological tumors is coming, and the live-streaming feast is about to begin!

The academic grand event on urological tumors is coming, and the live-streaming feast is about to begin!

Dear colleagues in the medical field, the 14th Shanghai Genitourinary Oncology Academic Conference & Annual Meeting of Chinese Anti-Cancer Association-Genital Oncology Committee (CACA-GO) will be held grandly from December 6th to 8th ! This is a "highlight moment" in the field of urology. It focuses on the cutting-edge progress and innovative achievements. Many top-notch experts and scholars from both home and abroad will gather together to conduct in-depth discussions, covering multiple aspects such as surgical innovation, basic research, and translational medicine, presenting a veritable "feast" of academic knowledge.
CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. "Hematology Frontier" specially invited the conference chair and the chairman of the Asian Cellular Therapy Organization (ACTO), Dr. Akihiro Shimosaka, to share his profound insights on immune cell therapy, regenerative medicine, gene therapy, and the application of exosomes.
CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.